Abstract
With the continual pressure to ensure follow-up molecules to billion dollar blockbuster drugs, there is a hurdle in profitability and growth for pharmaceutical companies in the next decades. With each success and failure we increasingly appreciate that a key to the success of synthesized molecules through the research and development process is the possession of drug-like properties. These properties include an adequate bioactivity as well as adequate solubility, an ability to cross critical membranes (intestinal and sometimes blood-brain barrier), reasonable metabolic stability and of course safety in humans. Dependent on the therapeutic area being investigated it might also be desirable to avoid certain enzymes or transporters to circumvent potential drug-drug interactions. It may also be important to limit the induction of these same proteins that can result in further toxicities. We have clearly moved the assessment of in vitro absorption, distribution, metabolism, excretion and toxicity (ADME/TOX) parameters much earlier in the discovery organization than a decade ago with the inclusion of higher throughput systems. We are also now faced with huge amounts of ADME/TOX data for each molecule that need interpretation and also provide a valuable resource for generating predictive computational models for future drug discovery. The present review aims to show what tools exist today for visualizing and modeling ADME/TOX data, what tools need to be developed, and how both the present and future tools are valuable for virtual filtering using ADME/TOX and bioactivity properties in parallel as a viable addition to present practices.
Similar content being viewed by others
References
Love, B., PSTT, 1 (1998) 89–90.
Cavalla, D., PSTT, 1 (1998) 91–92.
Kennedy, T., Drug Discovery Today, 2 (1997) 436–444.
Lipinski, C.A., Lombardo, F., Dominy, B.W. and Feeney, P.J., Adv. Drug. Del. Rev. 23 (1997) 3–25.
Lipinski, C.A., J. Pharm. Toxicol. Methods, 44 (2000) 235–249.
Lipinski, C.A., Curr. Drug Discovery, April (2001) 17–19.
Gillet, V.J., Willett, P. and Bradshaw, J., J. Chem. Inf. Comp. Sci., 38 (1998) 165–179.
Sadowski, J. and Kubinyi, H., J. Med. Chem., 41 (1998) 3325–3329.
Oprea, T.I., Davis, A.M., Teague, S.J. and Leeson, P.D., J. Chem. Inf. Comput. Sci., 41 (2001) 1308–1315.
Bemis, G.W. and Murcko, M.A., J. Med. Chem., 39 (1996) 2887–2893.
Bemis, G.W. and Murcko, M.A., J. Med. Chem., 42 (1999) 5095–5099.
Muegge, I., Heald, S.L. and Brittelli, D., J. Med. Chem., 44 (2001) 1–6.
Ekins, S., Ring, B.J., Bravi, G., Wikel, J.H. and Wrighton, S.A., (2000b) Predicting drug-drug interactions in silico using pharmacophores: A paradigm for the next millenium, in Pharmacophore, perception, development, and use in drug design (Guner OF ed) 269–299, University International Line, San Diego.
Ekins, S., Waller, C.L., Swaan, P.W., Cruciani, G., Wrighton, S.A. and Wikel, J.H., J. Pharm. Tox. Methods, 44 (2000d) 251–272.
Barratt, M.D., Env. Health. Perspectives., 106 (1998) 459–465.
Ekins, S., Ring, B.J., Grace, J., McRobie-Belle, D.J. and Wrighton, S.A., J. Pharm. Tox. Methods, 44 (2000c) 313–324.
Barratt, M.D. and Rodford, R.A., Curr. Opin. Chem. Biol., 5 (2001) 383–388.
Lombardo, F., Blake, J.F. and Curatolo, W.J., J. Med. Chem. 39 (1996) 4750–4755.
Ekins, S., Durst, G.L., Stratford, R.E., Thorner, D.A., Lewis, R., Loncharich, R.J. and Wikel, J.H., J. Chem. Inf. Comput. Sci., 41 (2001b) 1578–1586.
Stenberg, P., Norinder, U., Luthman, K. and Artursson, P., J. Med. Chem., 44 (2001) 1927–1937.
Walters, W.P., Stahl, M.T. and Murcko, M.A., Drug Discovery Today, 3 (1998) 160–178.
Leach, A.R. and Hann, M.M., Drug Discovery Today, 5 (2000) 326–336.
Barnum, D., Greene, J., Smellie, A. and Sprague, P., J. Chem. Inf. Comput. Sci. 36 (1996) 563–571.
Ekins, S., Bravi, G., Wikel, J.H. and Wrighton, S.A., J. Pharmacol. Exp. Ther., 291 (1999d) 424–433.
Chen, X., Rusinko, I., Tropsha, A. and Young, S.S., J. Chem. Inf. Comput. Sci., 39 (1999) 887–896.
Saiakhov, R., Stefan, L.R. and Klopman, G., Persp. Drug. Disc. Design., 19 (2000) 133–135.
Colmenarejo, G., Alvarez-Pedraglio, A. and Lavandera, J.-L., J. Med. Chem., 44 (2001) 4370–4378.
Crumb, Jr. W.J., Ekins, S., Sarazan, D., Wikel, J.H., Wrighton, S.A., Carlson, C. and Beasley, C., J. Clin. Psychiatry., (2002) in press.
Ekins, S., Crumb, W.J., Sarazan, R.D., Wikel, J.H. and Wrighton, S.A., J. Pharmacol. Exp. Ther., (2002) in press.
Manly, C.J., Louise-May, S. and Hammer, J.D., Drug Discovery Today, 6 (2001) 1101–1110.
Ekins, S., Bravi, G., Binkley, S., Gillespie, J.S., Ring, B.J., Wikel, J.H. and Wrighton, S.A., J. Pharmacol. Exp. Ther., 290 (1999b) 429–438.
Ekins, S., Bravi, G., Binkley, S., Gillespie, J.S., Ring, B.J., Wikel, J.H. and Wrighton, S.A., Pharmacogenetics, 9 (1999a) 477–489.
Ekins, S., Bravi, G., Binkley, S., Gillespie, J.S., Ring, B.J., Wikel, J.H. and Wrighton, S.A., Three and four dimensionalquantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors, 28 (2000a) 994–1002.
Ekins, S., de Groot, M. and Jones, J.P., Drug. Metab. Dispos., 29 (2001a) 936–944.
Bertz, R.J. and Granneman, R.G., Clin. Pharmacokinet., 32 (1997) 210–258.
Destroyer, A., Vander Heyden, Y., Carda-Broch, S., Garcia-Alvarez-Coque, M.C. and Massart, D.L. J. Chromatogr. A., 912 (2001) 211–221.
van de Waterbeemd, H., Smith, D.A. and Jones, B.C., J. Comput.-Aid. Mol. Des., 15 (2001) 273–286.
Stratford, R.E.J., Clay, M.P., Heinz, B.A., Kuhlfeld, M.T., Osborne, S.J., Phillips, D.L., Sweetan, S.A., Tebbe, M.J., Vasudevan, V., Zornes, L.L. and Lindstrom, T.D., J. Pharm. Sci., 88 (1999) 747–753.
Palm, K., Stenberg, P., Luthman, K. and Artursson, P., Pharm. Res., 14 (1997) 568–571.
Yazdanian, M., Glynn, S.L., Wright, J.L. and Hawi, A., Pharm. Res., 15 (1998) 1490–1494.
Palm, K., Luthman, K., Ungell, A.-L., Strandlund, G. and Artursson, P., J. Pharm. Sci., 85 (1996) 32–39.
Palm, K., Luthman, K., Ungell, A.-L., Strandlund, G., Beigi, F., Lundahl, P. and Artursson, P., J. Med. Chem., 41 (1998) 5382–5392.
Clark, D.E., J. Pharm. Sci., 88 (1999) 807–814.
Stenberg, P., Luthman, K., Ellens, H., Lee, C.P., Smith, P.L., Lago, A., Elliot, J.D. and Artursson, P., Pharm. Res., 16 (1999) 1520–1526.
Stenberg, P., Luthman, K. and Artursson, P., J. Control. Rel., 65 (2000) 231–243.
Ren, S. and Lien, E.J., Prog. Drug. Res., 54 (2000) 1–23.
Egan, W.J., Merz, K.M.J. and Baldwin, J.J., J. Med. Chem., 43 (2000) 3867–3877.
Schipper, N.G.M., Osterberg, T., Wrange, U., Westberg, C., Sokolowski, A., Rai, R., Young, W. and Sjostrom, B., Pharm. Res., 18 (2001) 1735–1741.
Oprea, T.I. and Gottfries, J., J. Mol. Graph. Model., 17 (1999) 261–274.
Ghuloum, A.M., Sage, C.R. and Jain, A.N., J. Med. Chem., 42 (1999) 1739–1748.
Andrews, C.W., Bennett, L. and Yu, L.X., Pharm. Res., 17 (2000) 639–644.
van de Waterbeemd, H., Camenenisch, G., Golkers, G. and Raevsky, O.A., QSAR, 15 (1996) 480–490.
Yoshida, F. and Topliss, J.G., J. Med. Chem., 43 (2000) 2575–2585.
Derringer, G. and Suich, R., J. Quality Technology, 12 (1980) 214–219.
Rassokin, D.N. and Agrafiotis, D.K., J. Mol. Graph. Model., 18 (2000) 368–382.
Agrafiotis, D.K., J. Chem. Inf. Comput. Sci., 41 (2002) 159–167.
Wrighton, S.A., Schuetz, E.G., Thummel, K.E., Shen, D.D., Korzekwa, K.R. and Watkins, P.B., Drug. Metab. Revs., 32 (2000) 339–361.
Gao, F., Johnson, D.L., Ekins, S., Janiszewski, J., K.G. K., Meyer, R.D. and West, M., (2001) Submitted.
Bursi, R., de Gooyer, M.E., Grootenhuis, A., Jacobs, P.L., van der Louw, J. and Leysen, D., J. Mol. Graph. Modelling., 19 (2001) 552–556.
Ekins, S. and Rose, J.P., J. Mol. Graph., 20 (2002) 305–309.
Lave, T., Dupin, S., Schmitt, C., Valles, B., Ubeaud, G., Chou, R.C., Jaeck, D. and Coassolo, P., Pharm. Res. 14 (1997) 152–155.
Schneider, G., Coassolo, P. and Lave, T., J. Med. Chem., 42 (1999) 5072–5076.
Ekins, S. and Obach, R.S., J. Pharmacol. Exp. Ther., 295 (2000) 463–473.
Quinones, C., Caceres, J., Stud, M. and Martinez, A., Quant Struct Act Rel., 19 (2000) 448–454.
Hansch, C., Drug Metabolism Reviews, 15 (1984) 1279–1294.
Cronin, M.T., Pharm. Pharmacol. Commun., 4 (1998) 157–163.
Richard, A.M., Toxicol. Lett., 102–103 (1998) 611–616.
Johnson, D.E. and Wolfgang, G.H.I., DDT, 5 (2000) 445–454.
Smith, C.J., Hansch, C. and Morton, M.J., Mutation Res., 379 (1997) 167–175.
Benigni, R., Passerini, L., Gallo, G., Giorgi, F. and Cotta-Ramusino, M., Env. Mol. Mutagenesis., 32 (1998) 75–83.
Mathews, E.J. and Contrera, J.F., Reg. Toxicol Pharmacol, 28 (1998) 242–264.
Tafozoli, M., Baeten, A., Geerlings, P. and Kirsch-Volders, M., Mutagenesis, 13 (1998) 115–126.
Llorens, O., Perez, J.J. and Villar, H.O., J. Med. Chem., 44 (2001) 2793–2804.
Stoffers, A.E.M.F., Boersma, M.G., Vaes, W.H.J., Vervoort, J., Tyrakowska, B., Hermens, J.L.M. and Rietjens, I.M.C.M., Toxicol in vitro, 15 (2001) 539–551.
Guilhermino, L., Diamantino, T., Silva, M.C. and Soares, A.M.V.M., Ecotoxicol Env. Safety, 46 (2000) 357–362.
Calleja, M.C., Persoone, G. and Geladi, P., Fd. Chem. Toxic., 32 (1994) 173–187.
Briens, F., Bureau, R. and Rault, S., Ecotxicol. Env. Safety., 43 (1999) 241–251.
Cronin, M.T.D. and Schultz, T.W., Chem. Res. Toxicol., 14 (2001) 1284–1295.
Kulkarni, A.S. and Hopfinger, A.J., Pharm. Res., 16 (1999) 1245–1253.
Patlewicz, G.Y., Rodford, R.A., Ellis, G. and Barratt, M.D., Toxicol in vitro, 14 (2000) 79–84.
Rekka, E.A. and Kourounakis, P.N., Eur. J. Drug Metab. Pharmacokinetics, 21 (1996) 7–11.
van der Burght, A.S.A.M., Clijsters, P.J., Horbach, G.J., Andersson, P.L., Tysklind, M. and van den Berg, M., Toxicol Appl. Pharmacol., 155 (1999) 13–23.
Schuetz, E.G., Beck, W.T. and Schuetz, J.D., Mol. Pharmacol., 49 (1996) 311–318.
Watkins, R.E., Wisely, G.B., Moore, L.B., Collins, J.L., Lambert, M.H., Williams, S.P., Willson, T.M., Kliewer, S.A. and Redinbo, M.R., Science, 292 (2001) 2329–2333.
Ekins, S. and Erickson, J.A., Drug. Metab. Dispos., 30 (2002) 96–99.
Ekins, S. and Schuetz, E., TIPS, (2002).
Honkakoski, P., Zelko, I., Sueyoshi, T. and Negishi, M., Mol. Cell. Biol., 18 (1998) 5652–5658.
Honkakoski, P., Jaaskelainen, I., Kortelahti, M. and Urtti, A., Pharm. Res. 18 (2001) 146–150.
Ekins, S., Bravi, G., Ring, B.J., Gillespie, T.A., Gillespie, J.S., VandenBranden, M., Wrighton, S.A. and Wikel, J.H., J. Pharmacol. Exp. Ther., 288 (1999c) 21–29.
Forman, B.M., Tzameli, I., Choi, H.-S., Chen, J., Simha, D., Seol, W., Evans, R.M. and Moore, D.D., Nature, 395 (1998) 612–614.
Bohm, H.-J. and Klebe, G., Angew. Chem. Int. Ed. Engl., 35 (1996) 2588–2614.
So, S.-S. and Karplus, M., J. Comput.-Aid. Mol. Des., 13 (1999) 243–258.
Shimada, J., Ishchenko, A.V. and Shakhnovich, E.I., Protein Sci., 9 (2000) 765–775.
Deisenhofer, J. and Michel, H., Annu. Rev. Biophys. Chem., 20 (1991a) 247–266.
Deisenhofer, J. and Michel, H., Annu. Rev. Cell. Biol., 7 (1991b) 1–23.
Unwin, N., Nature, 373 (1995) 37–43.
Tsukihara, T., Aoyama, H., Yamashita, E., Tomizaki, T., Yamaguchi, H., Shinzawa-Itoh, K., Nakashima, R., Yaono, R. and Yoshikawa, S., Science, 272 (1996) 1136–1144.
Chang, G. and Roth, C.B. Science, 293 (2001) 1793–1800.
Goswitz, V.C. and Brooker, R.J., Protein. Sci., 4 (1995) 534–537.
Kaback, H.R., Voss, J. and Wu, J., Curr. Opin. Struct. Biol., 7 (1997) 537–542.
Varela, M.F. and Wilson, T.H., Biochim. Biophys. Acta, 1276 (1996) 21–34.
Doolittle, R.F., Johnson, M.S., Husain, I., Van Houten, B., Thomas, D.C. and Sancar, A., Nature, 323 (1986) 451–453.
Baringhaus, K.H., Matter, H., Stenglin, S. and Kramer, W., J. Lipid Res., 40 (1999) 2158–2168.
Swaan, P.W., Szoka, F.C.J. and Oie, S., J. Comput. Aid. Mol. Des., 11 (1997) 581–588.
Zhang, E.H., Phelps, M.A., Helsper, F. and Swaan, P.W., (2002) submitted.
Zuniga, F.A., Shi, G., Haller, J.F., Rubashkin, A., Flynn, D.R., Iserovich, P. and Fischbarg, J., J. Biol. Chem., 276 (2001) 44970–44975.
Balimane, P.V., Tamai, I., Guo, A., Nakanishi, T., Kitada, H., Leibach, F.H., Tsuji, A. and Sinko, P.J., Biochem. Biophys. Res. Commun. 250 (1998) 246–251.
Han, H., de Vrueh, R.L., Rhie, J.K., Covitz, K.M., Smith, P.L., Lee, C.P., Oh, D.M., Sadee, W. and Amidon, G.L., Pharm. Res., 15 (1998) 1154–1159.
Palsson, B., Nature Biotechnology, 18 (2000) 1147–1150.
Ekins, S. and McGowan, R.J., Phil. Sci., 9 (2001) 1–23.
Pevzner, P.A., (2000) Computational molecular biology. MIT Press, Cambridge, MA.
Gerrard, J.A., Sparrow, A.D. and Wells, J.A., Trends Biochem Sci., 26 (2001) 137–140.
Wrighton, S.A. and Stevens, J.C., Crit. Rev. Toxicol., 22 (1992) 1–21.
Rendic, S. and Di Carlo, F.J., Drug Metab. Rev., 29 (1997) 413–580.
Ellis, L.B.M., Speedie, S.M. and McLeish, R., Bioinformatics, 14 (1998) 803–806.
Bower, J.M. and Bolouri, H., Computational modeling of genetic and biochemical networks. (2001) The MIT press, Cambridge, MA.
Dorner, D., (1996) The logic of failure. Perseus Books, Reading, MA.
Baxter, D.A., Canavier, C.C., Clark, Jr. J.W. and Byrne, J.H., J. Neurophysiol., 82 (1999) 2914–2935.
Cook, D.L. and Atkins, W.M., Biochemistry, 36 (1997) 10802–10806.
Noble, D. and Colatsky, T.J., Emerg. Ther. Targets, 4 (2000) 39–49.
Gifford, D.K., Science, 293 (2001) 2049–2051.
Darvas, F., Dorman, G. and Papp, A., J. Chem. Inf. Comput. Sci., 40 (2000) 314–322.
Ekins, S. and Wrighton, S.A., J. Pharm. Tox. Methods, 44 (2001) 1–5.
Hall, A.H., Toxicol. Lett., 102–103 (1998) 623–626.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ekins, S., Boulanger, B., Swaan, P.W. et al. Towards a new age of virtual ADME/TOX and multidimensional drug discovery. J Comput Aided Mol Des 16, 381–401 (2002). https://doi.org/10.1023/A:1020816005910
Issue Date:
DOI: https://doi.org/10.1023/A:1020816005910